220 related articles for article (PubMed ID: 7362733)
1. Effect of sulphinpyrazone on human platelet aggregation, 5-hydroxytryptamine release and adhesion ex vivo: comparison with naproxen.
Nunn B; James FJ
Br J Clin Pharmacol; 1980 Mar; 9(3):239-45. PubMed ID: 7362733
[TBL] [Abstract][Full Text] [Related]
2. Effect of nabumetone (BRL 14777), a new anti-inflammatory drug, on human platelet reactivity ex vivo: comparison with naproxen.
Nunn B; Chamberlain PD
J Pharm Pharmacol; 1982 Sep; 34(9):576-9. PubMed ID: 6127382
[TBL] [Abstract][Full Text] [Related]
3. The effect of sulphinpyrazone and its metabolites on platelet function in vitro and ex vivo.
Pay GF; Wallis RB; Zelaschi D
Haemostasis; 1981; 10(3):165-75. PubMed ID: 7262645
[TBL] [Abstract][Full Text] [Related]
4. Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig.
Chignard M; Wal F; Lefort J; Vargaftig BB
Eur J Pharmacol; 1982 Feb; 78(1):71-9. PubMed ID: 6804248
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of inhibitors of platelet release and aggregation.
Rosenberg JC; Sell TL
Arch Surg; 1975 Aug; 110(8):980-3. PubMed ID: 168838
[TBL] [Abstract][Full Text] [Related]
6. The effect of platelet function inhibitors on experimental venous thrombosis formation in rabbits.
Arfors KE; Bergqvist D; Tangen O
Acta Chir Scand; 1975; 141(1):40-2. PubMed ID: 1092111
[TBL] [Abstract][Full Text] [Related]
7. A study of the relationship between ex vivo and in vivo effects of sulphinpyrazone in the guinea pig.
Butler KD; Wallis RB; White AM
Haemostasis; 1979; 8(3-5):353-60. PubMed ID: 159853
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of phenylbutazone, naproxen and flunixin meglumine on equine platelet aggregation and platelet factor 3 availability in vitro.
Johnstone IB
Can J Comp Med; 1983 Apr; 47(2):172-9. PubMed ID: 6883184
[TBL] [Abstract][Full Text] [Related]
9. The effect of sulphinpyrazone on the aggregation and release reactions of human platelets.
Wiley JS; Chesterman CN; Morgan FJ; Castaldi PA
Thromb Res; 1979 Jan; 14(1):23-33. PubMed ID: 570742
[No Abstract] [Full Text] [Related]
10. A metabolite of sulphinpyrazone that is largely responsible for the effect of the drug on the platelet prostaglandin pathway.
Pay GF; Wallis RB; Zelaschi D
Biochem Soc Trans; 1980 Dec; 8(6):727-8. PubMed ID: 7461266
[No Abstract] [Full Text] [Related]
11. The effects of two different dosage regimens of sulphinpyrazone on platelet function ex vivo and blood chemistry in man.
Maguire ED; Pay GF; Turney J; Wallis RB; Weston MJ; White AM; Williams LC; Woods HF
Haemostasis; 1981; 10(3):153-64. PubMed ID: 7262644
[TBL] [Abstract][Full Text] [Related]
12. Collagen-induced platelet aggregation:--evidence against the essential role of platelet adenosine diphosphate.
Nunn B
Thromb Haemost; 1979 Dec; 42(4):1193-206. PubMed ID: 542929
[TBL] [Abstract][Full Text] [Related]
13. Effect of heparin on platelet monolayer adhesion, aggregation and production of malondialdehyde.
Davies JA; Menys VC
Thromb Res; 1982 Apr; 26(1):31-41. PubMed ID: 7101245
[TBL] [Abstract][Full Text] [Related]
14. Shape change and aggregation of blood platelets: interaction between the effects of adenosine and diphosphate, 5-hydroxytryptamine and adrenaline.
Michal F; Motamed M
Br J Pharmacol; 1976 Feb; 56(2):209-18. PubMed ID: 1252669
[TBL] [Abstract][Full Text] [Related]
15. Effects of 6-[p-(4-phenylacetylpiperazin-1-yl)phenyl]-4,5-dihydro-3(2H)pyridazinone (CCI 17810) and aspirin on platelet aggregation and adhesiveness.
Griffett EM; Kinnon SM; Kumar A; Lecker D; Smith GM; Tomich EG
Br J Pharmacol; 1981 Apr; 72(4):697-705. PubMed ID: 7284687
[TBL] [Abstract][Full Text] [Related]
16. Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid.
Brammer JP; Maguire MH
Br J Pharmacol; 1984 May; 82(1):61-72. PubMed ID: 6428500
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of platelet adhesion to rabbit aorta by sulphinpyrazone and acetylsalicylic acid.
Essien EM; Mustard JF
Atherosclerosis; 1977 May; 27(1):89-95. PubMed ID: 856231
[TBL] [Abstract][Full Text] [Related]
18. Proceedings: Refractoriness in blood platelets: effect of prior exposure to aggregating agents on subsequent aggregation responses.
Evans RJ; Gordon JL
Br J Pharmacol; 1974 May; 51(1):123P. PubMed ID: 4441772
[No Abstract] [Full Text] [Related]
19. Effect of contrast agents on platelet aggregation and 14C-serotonin release.
Zir LM; Carvalho AC; Hawthorne JW; Colman RW; Lees RS
N Engl J Med; 1974 Jul; 291(3):134-5. PubMed ID: 4833927
[No Abstract] [Full Text] [Related]
20. Pathways responsible for platelet hypersensitivity in rats with diabetes. I. Streptozocin-induced diabetes.
Winocour PD; Kinlough-Rathbone RL; Mustard JF
J Lab Clin Med; 1986 Feb; 107(2):148-53. PubMed ID: 3080538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
